The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Zovighian Bernard J since 2017.
This trader's CIK number is 1665141.
At the time of last reporting, Zovighian Bernard J was the CEO of Edwards Lifesciences Corp. (stock ticker symbol EW).
Also see all insider trading activities at Edwards Lifesciences Corp.
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2025 | EW | 0 | $0 | 29,210 | $2,194,265 | 14,925 | $675,758 |
2024 | EW | 580 | $49,730 | 8,617 | $755,538 | 6,265 | $0 |
2023 | EW | 0 | $0 | 0 | $0 | 5,003 | $0 |
2022 | EW | 0 | $0 | 23,429 | $2,287,540 | 12,600 | $0 |
2017 | EW | 0 | $0 | 18,050 | $1,971,312 | 20,000 | $1,337,200 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-05-30 | EW | Sale | 16,099 | 77.21 | 1,243,068 |
2025-06-03 | EW | Sale | 967 | 77.32 | 74,771 |
2025-05-05 | EW | Sale | 5,980 | 74.91 | 447,979 |
2025-05-05 | EW | Option Ex | 7,462 | 45.28 | 337,856 |
2025-03-10 | EW | Option Ex | 7,463 | 45.28 | 337,902 |
2025-03-10 | EW | Sale | 6,164 | 69.51 | 428,447 |
2024-05-30 | EW | Sale | 8,617 | 87.68 | 755,538 |
2024-05-06 | EW | Buy | 580 | 85.74 | 49,730 |
2024-05-04 | EW | Option Ex | 6,265 | .00 | 0 |
2023-05-07 | EW | Option Ex | 5,003 | .00 | 0 |
2022-08-05 | EW | Sale | 4,811 | 103.66 | 498,708 |
2022-06-14 | EW | Sale | 4,809 | 87.75 | 421,989 |
2022-05-31 | EW | Sale | 9,000 | 100.83 | 907,488 |
2022-05-24 | EW | Sale | 4,809 | 95.52 | 459,355 |
2022-05-08 | EW | Option Ex | 12,600 | .00 | 0 |
2017-04-27 | EW | Sale | 18,050 | 109.21 | 1,971,312 |
2017-04-27 | EW | Option Ex | 20,000 | 66.86 | 1,337,200 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Zovighian Bernard J (CEO of Edwards Lifesciences Corp at the time of this reporting) see the Securities and Exchange Commission (SEC) website.